California-based biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases Neuvivo announced on Wednesday that it has named Matthew William Davis, MD, RPh as its new chief medical officer.

Dr Davis has spearheaded FDA approval of QWO, Lidoderm and Colcrys, as well as FDA clearance of Sculptra. He has served as chief medical officer, chief scientific officer and chief operating officer, leading R&D departments at both publicly traded, multinational biopharmaceutical companies and small, privately held startups for the past 20 years. He currently has 17 active patents listed in the FDA Orange Book.

Ari Azhir, PhD, Neuvivo founder and CEO, said, 'I am delighted to have Dr Davis join our leadership team as he brings extensive experience navigating the regulatory approval process for various neurodegenerative diseases. This aligns nicely as we advance NP001 toward FDA submission. Dr Davis also brings exceptional experience with preparing rare disease products for commercialisation. His added passion for people with ALS and the advancement of transformative treatments will be essential for leading our medical efforts as we continue to progress in our journey to make a difference.'